THE DEAL, AT A GLANCE
From the announcementProQR Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedProQR Therapeutics raised $100M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersProQR Therapeutics is positioned around RNA editing therapy for inherited retinal diseases, with sepofarsen as the lead program for LCA10 and Axiomer as the next RNA…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
ProQR Therapeutics · Financing Record
Explore source-linked visual explanations for ProQR Therapeutics. Unsupported claims are withheld while source review continues.
Record 1446 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →